September 2025 Update on Information Relating to the General Meeting of September 30, 2025 – 61 Founding, Historical, Employee and Executive Shareholders of the Company, Representing Approximately 20.1% of Voting Rights have entered into a Shareholders’ Agreement
September 2025 OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer
September 2025 OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance – Publication of Circular for Combined Annual General Meeting of September 30, 2025
September 2025 OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
September 2025 OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
August 2025 OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
August 2025 OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting